Laminin-332 sustains chemoresistance and quiescence as part of the human hepatic cancer stem cell niche

Journal of Hepatology

Volumn 64, Issue 3, 2016, Pages 609-617

  Govaere, Olivier ^a   Wouters, Jasper ^a   Petz, Michaela ^b   Vandewynckel, Yves Paul ^c   Van Den Eynde, Kathleen ^a   Van Den Broeck, Anke ^a   Verhulst, Stefaan ^d   Dollé, Laurent ^d   Gremeaux, Lies ^e   Ceulemans, An ^a   Nevens, Frederik ^a   Van Grunsven, Leo A ^d   Topal, Baki ^a   Vankelecom, Hugo ^e   Giannelli, Gianluigi ^f   Van Vlierberghe, Hans ^c   Mikulits, Wolfgang ^b   Komuta, Mina ^a   Roskams, Tania ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c GHENT UNIVERSITY   (Belgium)

^d VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^e UNIVERSITY OF LEUVEN   (Belgium)

^f KU Leuven ^*  (Italy)

Author keywords

ATP binding cassette transporters; Cancer stem cell; Extracellular matrix; Hepatic cancer; Microenvironment; Niche; Phenotype switching

Indexed keywords

BIOLOGICAL MARKER; CYTOKERATIN 19; DOXORUBICIN; HISTONE H3; KALININ; LAMININ; LAMININ GAMMA2; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MESSENGER RNA; SORAFENIB; UNCLASSIFIED DRUG; CELL ADHESION MOLECULE; TARGET OF RAPAMYCIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILE DUCT CARCINOMA; CANCER RESISTANCE; CANCER STEM CELL; CELL PROLIFERATION; CONTROLLED STUDY; EXTRACELLULAR MATRIX; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LAMC2 GENE; LIVER CANCER CELL LINE; LIVER CELL CARCINOMA; MITOSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; STEM CELL NICHE; TUMOR XENOGRAFT; ANIMAL; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; LIVER NEOPLASMS; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; CELL ADHESION MOLECULES; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; KERATIN-19; LIVER NEOPLASMS; MICE; NEOPLASTIC STEM CELLS; STEM CELL NICHE; TOR SERINE-THREONINE KINASES;

EID: 84958849429     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2015.11.011     Document Type: Article

References (34)

1. B. Beck, and C. Blanpain Unravelling cancer stem cell potential Nat Rev Cancer 13 2013 727 738
2. T. Roskams Liver stem cells and their implication in hepatocellular and cholangiocarcinoma Oncogene 25 2006 3818 3822
3. T.A. Roskams, L. Libbrecht, and V.J. Desmet Progenitor cells in diseased human liver Semin Liver Dis 23 2003 385 396
4. Y.N. Kallis, A.J. Robson, J.A. Fallowfield, H.C. Thomas, M.R. Alison, N.A. Wright, and et al. Remodelling of extracellular matrix is a requirement for the hepatic progenitor cell response Gut 60 2011 525 533
5. S. Lorenzini, T.G. Bird, L. Boulter, C. Bellamy, K. Samuel, R. Aucott, and et al. Characterisation of a stereotypical cellular and extracellular adult liver progenitor cell niche in rodents and diseased human liver Gut 59 2010 645 654
6. V. Givant-Horwitz, B. Davidson, and R. Reich Laminin-induced signaling in tumor cells Cancer Lett 223 2005 1 10
7. O. Govaere, M. Komuta, J. Berkers, B. Spee, C. Janssen, F. de Luca, and et al. Keratin 19: a key role player in the invasion of human hepatocellular carcinomas Gut 63 2014 674 685
8. L. Sulpice, M. Rayar, M. Desille, B. Turlin, A. Fautrel, E. Boucher, and et al. Molecular profiling of stroma identifies osteopontin as an independent predictor of poor prognosis in intrahepatic cholangiocarcinoma Hepatology 58 2013 1992 2000
9. G. Giannelli, E. Fransvea, C. Bergamini, F. Marinosci, and S. Antonaci Laminin-5 chains are expressed differentially in metastatic and nonmetastatic hepatocellular carcinoma Clin Cancer Res 9 2003 3684 3691
10. G. Giannelli, A. Azzariti, E. Fransvea, L. Porcelli, S. Antonaci, and A. Paradiso Laminin-5 offsets the efficacy of gefitinib ('Iressa') in hepatocellular carcinoma cells Br J Cancer 91 2004 1964 1969
11. J. Tsurutani, K.A. West, J. Sayyah, J.J. Gills, and P.A. Dennis Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy Cancer Res 65 2005 8423 8432
12. M. Laplante, and D.M. Sabatini MTOR signaling in growth control and disease Cell 149 2012 274 293
13. T. Chiba, K. Kita, Y.W. Zheng, O. Yokosuka, H. Saisho, A. Iwama, and et al. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties Hepatology 44 2006 240 251
14. T. Chiba, S. Miyagi, A. Saraya, R. Aoki, A. Seki, Y. Morita, and et al. The polycomb gene product BMI1 contributes to the maintenance of tumor-initiating side population cells in hepatocellular carcinoma Cancer Res 68 2008 7742 7749
15. C. Hu, H. Li, J. Li, Z. Zhu, S. Yin, X. Hao, and et al. Analysis of ABCG2 expression and side population identifies intrinsic drug efflux in the HCC cell line MHCC-97L and its modulation by Akt signaling Carcinogenesis 29 2008 2289 2297
16. J.U. Marquardt, C. Raggi, J.B. Andersen, D. Seo, I. Avital, D. Geller, and et al. Human hepatic cancer stem cells are characterized by common stemness traits and diverse oncogenic pathways Hepatology 54 2012 1031 1042
17. A. Durnez, C. Verslype, F. Nevens, J. Fevery, R. Aerts, J. Pirenne, and et al. The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin Histopathology 49 2006 138 151
18. A. Golebiewska, N.H. Brons, R. Bjerkvig, and S.P. Niclou Critical appraisal of the side population assay in stem cell and cancer stem cell research Cell Stem Cell 8 2011 136 147
19. T. Yamashita, and X.W. Wang Cancer stem cells in the development of liver cancer J Clin Invest 123 2013 1911 1918
20. J. Bruix, G.J. Gores, and V. Mazzaferro Hepatocellular carcinoma: clinical frontiers and perspectives Gut 63 2014 844 855
21. A. Holczbauer, V.M. Factor, J.B. Andersen, J.U. Marquardt, D.E. Kleiner, C. Raggi, and et al. Modeling pathogenesis of primary liver cancer in lineage-specific mouse cell types Gastroenterology 145 2013 221 231
22. T. Borovski, E. De Sousa, F. Melo, L. Vermeulen, and J.P. Medema Cancer stem cell niche: the place to be Cancer Res 71 2011 634 639
23. G. Giannelli, B. Rani, F. Dituri, Y. Cao, and G. Palasciano Moving towards personalised therapy in patients with hepatocellular carcinoma: the role of the microenvironment Gut 63 2014 1668 1676
24. B. Pérez-Cadahía, B. Drobic, and J.R. Davie H3 phosphorylation: dual role in mitosis and interphase Biochem Cell Biol 87 2009 695 709
25. T.H. Cheung, and T.A. Rando Molecular regulation of stem cell quiescence Nat Rev Mol Cell Biol 14 2013 329 340
26. M. Maugeri-Saccà, P. Vigneri, and R. De Maria Cancer stem cells and chemosensitivity Clin Cancer Res 17 2011 4942 4947
27. J.L. Dembinski, and S. Krauss Characterization and functional analysis of a slow cycling stem cell-like subpopulation in pancreas adenocarcinoma Clin Exp Metastasis 26 2009 611 623
28. Y. Touil, W. Igoudjil, M. Corvaisier, A.F. Dessein, J. Vandomme, D. Monté, and et al. Colon cancer cells escape 5FU chemotherapy-induced cell death by entering stemness and quiescence associated with the c-Yes/YAP axis Clin Cancer Res 20 2014 837 846
29. B. Campos, Z. Gal, A. Baader, T. Schneider, C. Sliwinski, K. Gassel, and et al. Aberrant self-renewal and quiescence contribute to the aggressiveness of glioblastoma J Pathol 234 2014 23 33
30. A.V. Kurtova, J. Xiao, Q. Mo, S. Pazhanisamy, R. Krasnow, S.P. Lerner, and et al. Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance Nature 517 2014 209 213
31. M.S. Matter, T. Decaens, J.B. Andersen, and S.S. Thorgeirsson Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends J Hepatol 60 2014 855 865
32. M. Kaibori, N. Shikata, T. Sakaguchi, M. Ishizaki, K. Matsui, H. Iida, and et al. Influence of rictor and raptor expression of mTOR signaling on long-term outcomes of patients with hepatocellular carcinoma Dig Dis Sci 60 2014 919 928
33. O. Govaere, and T. Roskams Pathogenesis and prognosis of hepatocellular carcinoma at the cellular and molecular levels Clin Liver Dis 19 2015 261 276
34. Z.L. Xiang, Z.C. Zeng, Z.Y. Tang, J. Fan, P.Y. Zhuang, Y. Liang, and et al. Chemokine receptor CXCR4 expression in hepatocellular carcinoma patients increases the risk of bone metastases and poor survival BMC Cancer 9 2009 176